Case Report
BibTex RIS Cite

Alopecia areata after hepatitis C virus infection treatment: a case report

Year 2021, , 185 - 187, 24.04.2021
https://doi.org/10.38053/acmj.886644

Abstract

Interferon-free direct-acting antiviral (DAA) therapies in the chronic hepatitis C virus (HCV) infections have low side effects. Sofosbuvir / ribavirin (SOF / RBV) therapy combination is among in the currently approved treatment regimens. Aleopecia areata is a very rarely comlication of this treatment. A case of alopecia areata developed after SOF / RBV combination therapy in a patient with chronic hepatitis C infection is presented.

References

  • Naggie S, Wyles DL. Hepatitis c. In. Bennett JE, Dolin R, Blaser MJ (eds). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Ninth ed. Philadelphia, United States: Elsevier, 2020; 154: 2040-73.
  • Welzel TM, Nelson DR, Morelli G, et al. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut 2017; 66: 1844-52.
  • Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001.
  • Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Smira G, Regep L. The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey 2006 - 2008. J Gastrointestin Liver Dis 2010; 19: 373-379.
  • Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77
  • Bal T, Çabalak M. Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3. Ann Med Res 2020; 27: 2067-71.
  • Bakulin IG, Konstantin Z, Vasil Y, et Al. Sofosbuvır Plus ribavirin for the treatment of russian patients with chronic hcv genotype 1 or 3 infection. Hepatology Internatıonal 2015: 9; 52-58.
  • Kurtaran B, Sarıgül F, Çabalak M. Efficacy and safety of direct-acting antivirals in chronic hepatitis C patients infected with genotype 2 and 3 in Turkey. AASLD-TASL Connect Regional Meeting, 15-16 March, 2019. İstanbul, Turkey, 59-60.
  • Örmeci N, Gülşen MT, Sezgin O, et al. Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. Turk J Gastroenterol 2020; 31: 148-55.
  • Taliani G, Biliotti E, Capanni M,    Tozzi A, Bresci S, Pimpinelli N. Reversible alopecia universalis during treatment with PEG-interferon and ribavirin for chronic hepatitis C. J Chemother 2005; 17: 212-4.
  • Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142: 240-50.
  • Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 2006; 10: 1-183.
  • Maticic M, Poljak M, Lunder T, Rener-Sitar K, Stojanovic L. Lichen planus and other cutaneous manifestations in chronic hepatitis C: pre- and postinterferon-based treatment prevalence vary in a cohort of patients from low hepatitis C virus endemic area. J Eur Acad Dermatol Venereol 2008; 22: 779-88.
  • Podanyi B, Lengyel G, Harsing J, Becker K, Horvath A. Skin diseases associated with chronic hepatitis C. Orv Hetil 1998; 139: 2633-7.
  • Jadali Z, Mansouri P, Jadali F. These is no relationship between hepatitis C virus and alopecia areata. Eur J Dermatol 2006; 16: 94-5. 7. Geier DA, Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 2005; 38: 295-301.
  • Kartal ED, Alpat SN, Ozgunes I, Usluer G. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol 2007; 19: 817-20
Year 2021, , 185 - 187, 24.04.2021
https://doi.org/10.38053/acmj.886644

Abstract

References

  • Naggie S, Wyles DL. Hepatitis c. In. Bennett JE, Dolin R, Blaser MJ (eds). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Ninth ed. Philadelphia, United States: Elsevier, 2020; 154: 2040-73.
  • Welzel TM, Nelson DR, Morelli G, et al. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut 2017; 66: 1844-52.
  • Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001.
  • Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Smira G, Regep L. The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey 2006 - 2008. J Gastrointestin Liver Dis 2010; 19: 373-379.
  • Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77
  • Bal T, Çabalak M. Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3. Ann Med Res 2020; 27: 2067-71.
  • Bakulin IG, Konstantin Z, Vasil Y, et Al. Sofosbuvır Plus ribavirin for the treatment of russian patients with chronic hcv genotype 1 or 3 infection. Hepatology Internatıonal 2015: 9; 52-58.
  • Kurtaran B, Sarıgül F, Çabalak M. Efficacy and safety of direct-acting antivirals in chronic hepatitis C patients infected with genotype 2 and 3 in Turkey. AASLD-TASL Connect Regional Meeting, 15-16 March, 2019. İstanbul, Turkey, 59-60.
  • Örmeci N, Gülşen MT, Sezgin O, et al. Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. Turk J Gastroenterol 2020; 31: 148-55.
  • Taliani G, Biliotti E, Capanni M,    Tozzi A, Bresci S, Pimpinelli N. Reversible alopecia universalis during treatment with PEG-interferon and ribavirin for chronic hepatitis C. J Chemother 2005; 17: 212-4.
  • Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142: 240-50.
  • Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 2006; 10: 1-183.
  • Maticic M, Poljak M, Lunder T, Rener-Sitar K, Stojanovic L. Lichen planus and other cutaneous manifestations in chronic hepatitis C: pre- and postinterferon-based treatment prevalence vary in a cohort of patients from low hepatitis C virus endemic area. J Eur Acad Dermatol Venereol 2008; 22: 779-88.
  • Podanyi B, Lengyel G, Harsing J, Becker K, Horvath A. Skin diseases associated with chronic hepatitis C. Orv Hetil 1998; 139: 2633-7.
  • Jadali Z, Mansouri P, Jadali F. These is no relationship between hepatitis C virus and alopecia areata. Eur J Dermatol 2006; 16: 94-5. 7. Geier DA, Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 2005; 38: 295-301.
  • Kartal ED, Alpat SN, Ozgunes I, Usluer G. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol 2007; 19: 817-20
There are 16 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Case Report
Authors

Esma Eroğlu 0000-0002-0181-6023

Publication Date April 24, 2021
Published in Issue Year 2021

Cite

AMA Eroğlu E. Alopecia areata after hepatitis C virus infection treatment: a case report. Anatolian Curr Med J / ACMJ / acmj. April 2021;3(2):185-187. doi:10.38053/acmj.886644

TR DİZİN ULAKBİM and International Indexes (1b)

Interuniversity Board (UAK) Equivalency:  Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS]

Note: Our journal is not WOS indexed and therefore is not classified as Q.

You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/3449/file/4924/show

Journal Indexes and Platforms: 

TR Dizin ULAKBİM, Google Scholar, Crossref, Worldcat (OCLC), DRJI, EuroPub, OpenAIRE, Turkiye Citation Index, Turk Medline, ROAD, ICI World of Journal's, Index Copernicus, ASOS Index, General Impact Factor, Scilit.


The indexes of the journal's are;

18596


asos-index.png

f9ab67f.png

WorldCat_Logo_H_Color.png

      logo-large-explore.png

images?q=tbn:ANd9GcQgDnBwx0yUPRKuetgIurtELxYERFv20CPAUcPe4jYrrJiwXzac8rGXlzd57gl8iikb1Tk&usqp=CAU

index_copernicus.jpg


84039476_619085835534619_7808805634291269632_n.jpg





The platforms of the journal's are;

COPE.jpg

images?q=tbn:ANd9GcTbq2FM8NTdXECzlOUCeKQ1dvrISFL-LhxhC7zy1ZQeJk-GGKSx2XkWQvrsHxcfhtfHWxM&usqp=CAUicmje_1_orig.png

cc.logo.large.png

ncbi.png

ORCID_logo.pngimages?q=tbn:ANd9GcQlwX77nfpy3Bu9mpMBZa0miWT2sRt2zjAPJKg2V69ODTrjZM1nT1BbhWzTVPsTNKJMZzQ&usqp=CAU


images?q=tbn:ANd9GcTaWSousoprPWGwE-qxwxGH2y0ByZ_zdLMN-Oq93MsZpBVFOTfxi9uXV7tdr39qvyE-U0I&usqp=CAU






The
 
indexes/platforms of the journal are;

TR Dizin Ulakbim, Crossref (DOI), Google Scholar, EuroPub, Directory of Research Journal İndexing (DRJI), Worldcat (OCLC), OpenAIRE, ASOS Index, ROAD, Turkiye Citation Index, ICI World of Journal's, Index Copernicus, Turk Medline, General Impact Factor, Scilit 


EBSCO, DOAJ, OAJI is under evaluation.

Journal articles are evaluated as "Double-Blind Peer Review"